Hey Thomas Edison,
I guess burying and lying about the results can really add to the cost. Yet another class action lawsuit for the folks at mnk. Is the lying really a surprise at this point? seems to be a core value of mnk employees.
“According to the Complaint, the Company made false and misleading statements to the market. Mallinckrodt’s H.P. Acthar Gel (“Acthar”) was a non-viable treatment for ALS based on serious safety concerns. Despite these safety issues, the Company touted Acthar as a viable ALS treatment. Based on these facts, the Company’s statements were false and materially misleading throughout the class period. When the market learned the truth about Mallinckrodt, investors suffered damages.”